xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
BOSTON, Feb. 20, 2018 -- resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced that Joan Mannick, M.D., Chief Medical Officer, will present a company overview at the 2018 RBC Capital Markets Global Healthcare Conference on Thursday, February 22, 2018 at 2:05 p.m. ET in New York.
A live webcast of the presentation can be accessed on the Investors section of resTORbio’s website at http://ir.restorbio.com/investors.
About resTORbio
resTORbio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio’s lead program focuses on selective inhibition of the target of rapamycin complex 1 (TORC1) pathway to treat aging-related diseases with an initial focus on diseases caused by immunosenescence, the decline in immune function that occurs during aging.
Contacts:
Beth DelGiacco
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Michael Lampe
Scient PR
484-575-5040
[email protected]
